Mesenkia Therapeutics AB
559443-7021ActiveDeveloping novel antibodies to treat aggressive brain cancer glioblastoma.
Oversikt
- 2
- Ansatte
- 0 SEK
- Omsetning
- 2023
- Grunnlagt
Beskrivelse
Mesenkia is a pre-clinical biotechnology company focused on developing breakthrough therapies for glioblastoma, an aggressive form of brain cancer. The company specializes in creating next-generation biological drug candidates, specifically single domain antibodies. Their scientific foundation stems...
Tagger
Nøkkelord
Bedriftsinformasjon
- Bransje
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- MVA-nummer
- SE559443702101
Beslutningstakere
Ingen beslutningstakere funnet ennå
Lignende bedrifter
20 lignende bedrifter i FunnelfeedrOblique Therapeutics AB (publ)
10–19 ansatteInnovative biotech developing breakthrough antibodies using the AbiProt platform.
Sang Biotech AB
0 ansatteDeveloping novel antibody therapeutics for kidney and cardiovascular diseases.
Affibody Medical AB
Developing next-generation radiopharmaceuticals using proprietary Affibody platform.
PILA PHARMA AB
1–4 ansatteClinical stage biotech developing an oral obesity and diabetes treatment.
Affibody AB
50–99 ansatteDeveloping next-generation radiopharmaceuticals using proprietary Affibody technology.
Utforsk mer
Spørsmål om Mesenkia Therapeutics AB
Vil du se Funnelfeedr i aksjon?
Book en gratis demo og oppdag hvordan Funnelfeedr hjelper deg med å finne og konvertere dine ideelle kunder.
Book en demo